Galapagos NV Appoints Aaron Cox as New CFO

The latest update is out from Galapagos ( (GLPG) ).

On June 23, 2025, Galapagos NV announced the appointment of Aaron Cox as the new Chief Financial Officer, effective July 7, 2025. Aaron Cox, formerly of Horizon Therapeutics, brings extensive experience in international corporate finance and M&A, having played a significant role in Horizon’s acquisition by Amgen. This leadership change is expected to accelerate Galapagos’ pipeline growth and strategic financial management, potentially impacting its industry positioning and stakeholder value.

The most recent analyst rating on (GLPG) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.

Spark’s Take on GLPG Stock

According to Spark, TipRanks’ AI Analyst, GLPG is a Neutral.

Galapagos’s overall stock score is driven by its financial stability and strong cash reserves, offset by significant profitability and cash flow challenges. Technical indicators show a mildly positive trend, while valuation remains unattractive due to negative earnings. The earnings call highlights strategic initiatives and a robust pipeline, but high restructuring costs and expected cash burn are notable risks.

To see Spark’s full report on GLPG stock, click here.

More about Galapagos

Galapagos is a biotechnology company with operations in Europe, the U.S., and Asia, focused on transforming patient outcomes through innovative science and technology. The company targets high unmet medical needs, creating a pipeline of best-in-class medicines, and is committed to challenging the status quo in healthcare. Galapagos has capabilities from lab to patient, including a decentralized cell therapy manufacturing platform, aiming to deliver results for patients, employees, and shareholders.

Average Trading Volume: 388,261

Technical Sentiment Signal: Sell

Current Market Cap: $1.79B

For an in-depth examination of GLPG stock, go to TipRanks’ Overview page.